PTCA Catheter Reclassification Panel Meeting

December 4, 2000

- Introductory Remarks (FDA)
- · Petitioner Presentation
- · Presentation of Questions for the Panel
- Completion of Reclassification Questionnaires

Lyaette Gabriel FDA/CDRH/DCRE

Regulatory	History	of PTCA
Cathe	eters	

- First PMA received in 1979 and approved in 1980
- 20 original PMAs approved to date
 most recent in 1999
- 820 PMA supplements approved

 supplements often represent new models

Lynette Gabriel FDA/CDRH/DCRD

Devices Under Consideration

- · Per proposed device description
 - A PTCA balloon catheter has a single or double lumen shaft with a balloon near the distal tip. The catheter typically features a minimally compliant balloon constructed from a high density polymer. The balloon is designed to uniformly expand to a specified diameter and length at a specific pressure as labeled, with acceptable rates of inflation and deflation and acceptable burst pressure. The device generally features a type of radiographic marker to facilitate fluoroscopic visualization of the balloon during use.

Lynette Gabriel FOA/CORH/OCR

raci in acceptal community	0268	. 00	0EC -8	A9:55
	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·		<u> Santa de la composición dela composición de la composición de la composición de la composición de la composición dela composición dela composición dela composición de la co</u>
	·	·		
				
			a, a, — ada garana a, i — i a	
		***************************************		n and sugar mentals and and a second sugar section.
endig Telling van gewoen gebe	an Connection of Contraction of the Section of the			and the second second
	·			
		· · · · · · · · · · · · · · · · · · ·		and the second s
				est o gamente de comp
 				n descent Se i de Alba (base)
			•	
			·	

Devices Under Consideration

- · For proposed indication for use
 - Intended for balloon dilatation of a hemodynamically significant coronary artery or bypass graft stenosis in patients evidencing coronary ischemia for the purpose of improving myocardial perfusion

Lynette Gabriel FDA/CDRH/DCRE

MAUDE Database Adverse Events

- · Balloon Rupture
- · Removal Difficulties
- · Balloon Burst
- Separation.
- · Device Breakage
- Sticking

- · Deflation Difficulties
- Tip Breakage
- · Inflation Difficulties
- · Insertion Difficulties
- Device or Fragments Remain in Patient

Lynette Gabriel FDA/CDRH/DCRD

Comments Received

- · Agree with proposal to downclassify PTCA catheters
- · Reclassification should apply only to "standard" PTCA catheters
- · Concern about the use of PTCA catheters to treat in-stent restenosis
- Suggestions for FDA guidance document

Lynette Gabriel FDA/CORH/OCRO

	 	 			

PTCA Catheter Reclassification Questions for the Panel rtte Gabriel FDA/CDRH/DCRD **Proposed Device Description** A PTCA balloon catheter has a single or double lumen shaft with a balloon near the distal tip. The catheter typically features a minimally compliant balloon constructed from a high density polymer. The balloon is designed to uniformly expand to a specified diameter and length at a specific pressure as labeled, with acceptable rates of inflation and deflation and acceptable burst pressure. The device generally features a type of radiographic marker to facilitate fluoroscopic visualization of the balloon during use. Question for the Panel • Does the proposed classification description sufficiently describe PTCA catheters?

Lynette Gabriel FDA/CDRH/DCRD

3

Proposed Risks to Health

- · Acute Vessel Closure
- Dissection/Perforation
- Acute MI/Unstable Angina
- Coronary Artery Spasm
- Arrhythmia
- Embolization
- Hypotension/Hypertension
- Stroke
- Reaction to Contrast Agent
- Failed Procedure
- Coagulopathy
- **Aneurysm Formation**
- Vascular Access Site
- Complications Restenosis
- **Emergency Bypass Surgery**
- Death
- Balloon Rupture
- Guidewire Fracture/Entrapment

Lynette Gabriel FDA/CDRH/DCRD

Question for the Panel

- · Have the health risks associated with PTCA catheters been adequately identified?
- If not, what are the additional risks that should be described?

Lynette Gabriel FDA/CDRH/DCRD

Proposed Special Controls

- · Guidance Document
- Device Labeling

Question for the Panel

- Have the appropriate special controls been identified to adequately address the risks to health specific to PTCA catheters?
- If not, what additional special controls are necessary to reclassify PTCA catheters?

Lynette Gabriel FDA/CDRH/DCRD